Welcome to our dedicated page for Nevro news (Ticker: NVRO), a resource for investors and traders seeking the latest updates and insights on Nevro stock.
Overview
Nevro Corp (NYSE: NVRO) is a global medical device company headquartered in Redwood City, California. The company is renowned for its innovative approach in the field of neuromodulation and chronic pain management, providing advanced spinal cord stimulation (SCS) systems designed to transform patient outcomes. Nevro specializes in the development and commercialization of its flagship Senza SCS system, which uniquely delivers its proprietary 10 kHz high-frequency therapy. This evidence-based treatment is implemented through a comprehensive, integrated platform aimed at alleviating chronic pain across multiple conditions.
Technology and Innovation
Nevro’s technology centers on generating electrical impulses that modulate pain signals. The Senza system, along with the broader HFX platform, is built on groundbreaking research and clinical evidence. Its design incorporates sophisticated programming and, more recently, artificial intelligence enhancements through HFX AdaptivAI. This AI-driven component harnesses big data, precise algorithms, and extensive clinical outcomes to offer personalized, real-time pain relief. As a result, patients are empowered to control their pain management in a manner that is tailored to their individual needs, reducing reliance on generalized treatments.
Product Portfolio and Market Position
The company has established a diversified portfolio that not only focuses on conventional SCS devices but also extends into minimally invasive treatments for sacroiliac (SI) joint pain and fusion procedures. By broadening its offerings, Nevro addresses various facets of chronic pain, including back pain, painful diabetic neuropathy, and SI joint dysfunction. This strategic diversification enables Nevro to maintain a unique competitive edge in a market characterized by substantial underpenetration and evolving treatment protocols.
Patient and Physician Support
An integral part of Nevro’s approach lies in its comprehensive support services. The company provides extensive educational resources and application support via programs like HFX Coach, designed to ensure that patients receive continuous guidance throughout their therapy journey. Alongside patient-centric initiatives, Nevro offers advanced, cloud-based insights for physicians, empowering them with real-time data to optimize treatment plans and enhance overall practice management.
Global Reach and Regulatory Milestones
Nevro’s neuromodulation solutions are commercially available in major markets such as the United States, Europe, and Australia. Over the years, the company has successfully achieved key regulatory approvals, including CE Mark and FDA clearance, which attest to the safety, efficacy, and scientific rigor underlying its products. These milestones have not only reinforced Nevro’s position in the global medical device arena but have also paved the way for further market penetration and adoption of its innovative therapies.
Competitive Landscape and Differentiators
Operating in a highly competitive healthcare sector, Nevro differentiates itself through an unwavering commitment to evidence-based medicine and technological innovation. Its products are developed with the dual aim of delivering consistent pain relief while also ensuring a high quality of life for patients. The use of advanced AI, coupled with extensive clinical validation, positions Nevro as an authoritative entity in chronic pain treatment options. This unique amalgamation of rigorous clinical research, technological sophistication, and robust support services sets Nevro apart from its peers in the neuromodulation industry.
Conclusion
Nevro Corp remains dedicated to advancing chronic pain management through its cutting-edge medical devices and holistic care solutions. With a focus on developing technologies that are not only innovative but also grounded in robust clinical evidence, Nevro continues to enhance patient outcomes and redefine approaches to pain management across global markets.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain treatment, announced that its Chairman and CEO, Keith Grossman, CFO Rod MacLeod, and CMO David Caraway will participate in the Wells Fargo 2022 MedTech R&D Spotlight Call Series on March 4, 2022, at 10:00 AM ET. The event will provide insights into Nevro's innovative solutions, including the proprietary 10 kHz Therapy. Investors can access a live webcast and archived recording on Nevro's website. For ongoing updates, Nevro encourages stakeholders to regularly visit their Investor Relations section.
Nevro Corp. (NYSE: NVRO) has published 12-month data from the SENZA-NSRBP randomized controlled trial in the Journal of Neurosurgery: Spine. The study highlights the effectiveness of high-frequency 10 kHz spinal cord stimulation (SCS) in treating non-surgical refractory back pain, showing that 78.2% of patients reported pain relief greater than 50%. The study involved 121 patients and demonstrated consistent safety, with a low explant rate of 2.1% and a significant 46% reduction in opioid use. Nevro is positioned uniquely with FDA approval for this therapy.
Nevro Corp. (NYSE: NVRO), a leader in chronic pain solutions, announced that its Chairman, CEO, and President, D. Keith Grossman, will present at Citi's 2022 Virtual Healthcare Conference on February 24, 2022, at 12:30 pm Eastern Time. A webcast will be available on their website. Nevro has developed the innovative 10 kHz Therapy, which has benefited over 80,000 patients globally, significantly impacting chronic pain treatment.
Nevro Corp. has responded to Medtronic's FDA approval for painful diabetic neuropathy (PDN), highlighting the significant market potential for this condition. The company asserts its SENZA-PDN trial is the largest and most comprehensive for spinal cord stimulation therapy, yielding superior outcomes compared to Medtronic's studies. Nevro claims its proprietary 10 kHz Therapy offers advantages in pain relief, treatment success rates, and neurological improvement. The company expresses concern over Medtronic's reliance on older studies for FDA approval, emphasizing the robust data from their SENZA-PDN trial.
Nevro Corp. (NYSE: NVRO), a medical device company, will announce its fourth quarter and full-year 2021 financial results on February 23, 2022. The report will be released after market close, followed by a conference call at 1:30 PM PT to discuss the results. Interested investors can access the call by dialing (888) 330-2443 or +1 (240) 789-2728 internationally, using Conference ID: 3583097. Nevro, based in Redwood City, California, specializes in chronic pain solutions and is known for its 10 kHz Therapy benefiting over 80,000 patients worldwide.
Nevro Corp. (NYSE: NVRO), based in Redwood City, California, has received FDA approval for expanded labeling of its Senza® Spinal Cord Stimulation (SCS) System to treat Non-Surgical Refractory Back Pain (NSRBP), marking it the only SCS system specifically indicated for this condition. This approval highlights Nevro's proprietary 10 kHz Therapy. Clinical trials indicate significant improvements in pain relief and quality of life for patients after 12 months of treatment. Nevro aims to enhance market access and payer coverage based on these results.
Nevro Corp. announced significant outcomes from its clinical trials presented at the 2022 North American Neuromodulation Society Annual Meeting. The SENZA-PDN trial demonstrated durable efficacy for 10 kHz spinal cord stimulation in painful diabetic neuropathy at 18 months, with no explants due to loss of efficacy. The SENZA-NSRBP trial showed profound pain relief and improved quality of life in patients at 12 months, supported by cost-effectiveness data for the treatment. Nevro aims to be the only SCS company with an on-label indication for treating non-surgical refractory back pain upon FDA approval.
Nevro Corp. (NYSE: NVRO) reported preliminary unaudited revenue results for Q4 and full-year 2021, expecting Q4 revenue of approximately $102.5 million, down from $109.7 million YoY. Full-year revenue is expected at $386.6 million, up from $362.0 million in 2020. Despite Q4 declines, U.S. trial procedures rose 3%, with painful diabetic neuropathy (PDN) trials growing 92% sequentially. Nevro anticipates exceeding its adjusted EBITDA guidance of negative $10 million to negative $13 million. The company plans to report full financial results on February 23, 2022.
Nevro Corp. (NYSE: NVRO) announced that UnitedHealthcare will provide coverage for its high-frequency 10 kHz Therapy for Painful Diabetic Neuropathy (PDN), effective March 1, 2022. This decision is seen as a major milestone in facilitating access to Nevro's FDA-approved spinal cord stimulation therapy. UnitedHealthcare’s policy considers this treatment medically necessary under specific criteria. Nevro believes this coverage will enhance its market position and lead to further endorsements from additional health plans, supported by extensive clinical data.
Nevro Corp. (NYSE: NVRO) announced a settlement of its patent lawsuit against Nalu Medical regarding high-frequency spinal cord stimulation (SCS) technology. Initially filed in February 2020, Nevro accused Nalu of patent infringement, but the lawsuit concluded with both parties agreeing to avoid further litigation costs. Nevro's General Counsel, Kashif Rashid, emphasized the importance of protecting intellectual property. Nevro remains the sole provider of FDA-approved high-frequency SCS therapy for painful diabetic neuropathy, allowing them to focus on developing solutions for chronic pain.
FAQ
What is the current stock price of Nevro (NVRO)?
What is the market cap of Nevro (NVRO)?
What is Nevro Corp's primary business?
Which products form the core of Nevro's portfolio?
How does Nevro's spinal cord stimulation system work?
In which markets are Nevro's products available?
What role does technology play in Nevro's treatments?
How does Nevro support its patients and healthcare providers?
What differentiates Nevro from other pain management companies?
What conditions do Nevro's therapies target?
